Macular Degeneration Therapeutics Market in Asia-Pacific to 2019

  • 90 views
Uploaded on

Macular Degeneration Therapeutics Market in Asia-Pacific @ …

Macular Degeneration Therapeutics Market in Asia-Pacific @ http://www.researchmoz.us/macular-degeneration-therapeutics-market-in-asia-pacific-to-2019-existing-angiogenics-retain-dominance-though-high-unmet-need-remains-report.html

The Report provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
90
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains GBI Research has released its research, “ Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains”, which provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products. GBI Research analysis shows that the APAC ophthalmology market for macular degeneration was valued at $675.7m in 2012. The market is expected to grow at a Compounded Annual Growth Rate (CAGR) of 6% for the forecast period and will reach $1,016m by 2019. Increase in the aging population and high annual cost of therapy of the marketed drugs are expected to drive the market valuations through 2019. However, the predominant off-label usage of Avastin for the treatment of the disease especially in developing countries like India and China act as a major barrier for growth of the market during the forecast period. Scope Disease overview along with treatment algorithms and treatment usage patterns Market size and forecast for the macular degeneration market in APAC from 2012 to 2019 Major marketed products in the APAC along with a heat map In-depth analysis of pipeline along with clinical trial failure analysis Key drivers and restraints that have had a significant impact on the market Key licensing and co-development agreements in the macular degeneration market Reasons to Buy Align your product portfolio to the markets with high growth potential Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the macular degeneration market Develop key strategic initiatives by understanding the key focus areas and leading companies Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships table Of Content 1 Table Of Contents 1.1 List Of Tables 1.2 List Of Figures Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Re
  • 2. 2 Macular Degeneration Asia-pacific Market To 2019 – Introduction 2.1 Symptoms 2.2 Etiology 2.3 Pathophysiology 2.3.1 Disease Initiation 2.3.2 Disease Propagation 2.4 Classification 2.4.1 Early Amd 2.4.2 Intermediate Amd 2.4.3 Advanced Amd 2.5 Co-morbidities And Complications 2.6 Diagnosis 2.6.1 History 2.6.2 Examination 2.6.3 Diagnostic Tests 2.7 Epidemiology 2.8 Prognosis And Disease Staging 2.9 Treatment Options 2.9.1 Pharmacological 2.9.2 Treatment Algorithms And Prescribing Habits 2.9.3 Non-pharmacological Care 3 Macular Degeneration Asia-pacific Market To 2019 – Marketed Products 3.1 Therapeutic Landscape 3.1.1 Lucentis (ranibizumab) – Novartis Ag/roche (genentech) 3.1.2 Eylea (aflibercept) – Regeneron Pharmaceuticals/bayer Healthcare 3.1.3 Avastin (bevacizumab) – Genentech (roche) 3.1.4 Macugen (pegaptanib Sodium) – Valeant Pharmaceuticals/pfizer 3.1.5 Visudyne (verteporfin Injection) – Novartis Ag 3.1.6 Triamcinolone Acetonide 3.2 Comparative Efficacy And Safety 4 Macular Degeneration Asia-pacific Market To 2019 – Pipeline For Disease 4.1 Overall Pipeline 4.2 Pipeline Analysis By Molecule Type 4.3 Pipeline Analysis By Mechanism Of Action 4.4 Clinical Trials 4.4.1 Failure Rate 4.4.2 Clinical Trial Duration 4.4.3 Clinical Trial Size 4.5 Promising Drug Candidates In The Pipeline Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Re
  • 3. 4.5.1 Mc-1101 – Macuclear, Inc. 4.5.2 Kh902 (fumintide) – Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 5 Macular Degeneration Asia-pacific Market To 2019 – Market Forecast To 2019 5.1 Geographical Markets 5.1.1 Apac Market 5.1.2 Australia 5.1.3 China 5.1.4 India 5.1.5 Japan 5.2 Drivers And Barriers For The Disease Market 5.2.1 Drivers 5.2.2 Barriers 6 Macular Degeneration Asia-pacific Market To 2019 – Deals And Strategic Consolidations 6.1 Deals Analysis 6.2 Major Co-development Deals 6.2.1 Sinphar Enters Into Co-development Agreement With Macuclear 6.2.2 Allergan Enters Into Co-development Agreement With Molecular Partners 6.2.3 X-body Biosciences Enters Into Co-development Agreement With Hengrui Medicine For Amd 6.2.4 Alcon Enters Into Collaboration With Astrazeneca 6.2.5 Acucela Enters Into Co-development Agreement With Otsuka Pharma For Acu-4429 6.3 Major Licensing Deals 6.3.1 Allegro Ophthalmics Enters Into Licensing Agreement With Senju Pharma To Develop Integrin Peptide Therapy 6.3.2 Allergan Enters Into Licensing Agreement With Molecular Partners 6.3.3 Panoptica Enters Into Licensing Agreement With Osi Pharma 6.3.4 Lpath Enters Into Licensing Agreement With Pfizer 6.3.5 Shionogi Enters Into Licensing Agreement With Oncotherapy Science 7 Macular Degeneration Asia-pacific Market To 2019 – Appendix 7.1 All Pipeline Drugs By Phase 7.1.1 Discovery 7.1.2 Preclinical 7.1.3 Ind-filed And Phase 0 7.1.4 Phase I 7.1.5 Phase Ii 7.1.6 Phase Iii 7.1.7 Undisclosed 7.2 Market Forecasts To 2019 Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Re
  • 4. 7.2.1 Asia-pacific 7.2.2 Australia 7.2.3 China 7.2.4 India 7.2.5 Japan 7.3 Market Definitions 7.4 Abbreviations 7.5 References 7.6 Research Methodology 7.6.1 Coverage 7.6.2 Secondary Research 7.6.3 Primary Research 7.6.4 Therapeutic Landscape 7.6.5 Geographical Landscape 7.6.6 Pipeline Analysis 7.7 Expert Panel Validation 7.8 Contact Us 7.9 Disclaimer ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Re